Immunotherapy for malignant melanoma with a tumor cell vaccine.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 1642395.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Specific active immunotherapy for melanoma has been administered to several thousand patients since 1972, using an irradiated whole-cell preparation. A humoral response to vaccination can be demonstrated in a large percentage of patients. This response increases while immunizations are continued and decreases after cessation of therapy. The vaccinations are well tolerated; however, the therapeutic impact of this whole-cell vaccine awaits a randomized trial for definitive evaluation.
Medical subject headings
- BCG Vaccine
- Immunotherapy, Active
- Melanoma
- Skin Neoplasms